Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: GregorioAllegri who wrote (4187)	4/13/2016 10:43:56 PM
From: jaybe	Read Replies (1) \| Respond to of 4474

The patent only generally describes potency, as in IC50s below 100nM get an 'A' for select EGFR and Her2 mutations/insertions. Separately the 'summary of invention' describes compounds with picomolar potency for both EGFR and Her2. Hopefully the AACR poster will shed light on activity against off-target kinases, but with ~6,000 patients in the US dying every year with Exon 20 mutations in NSCLC I expect we will learn more about safety directly from patients on trial in about 6-8 months. Timing is right for '788 to be a late-breaker at ASCO 2017.